While Haemonetics Corp has underperformed by -0.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HAE fell by -14.03%, with highs and lows ranging from $97.97 to $69.29, whereas the simple moving average fell by -11.70% in the last 200 days.
On December 06, 2024, JP Morgan started tracking Haemonetics Corp (NYSE: HAE) recommending Overweight. A report published by Raymond James on November 08, 2024, Upgraded its rating to ‘Strong Buy’ for HAE. CL King also rated HAE shares as ‘Buy’, setting a target price of $116 on the company’s shares in an initiating report dated September 13, 2024. BofA Securities Initiated an Neutral rating on September 11, 2024, and assigned a price target of $85. BTIG Research initiated its ‘Buy’ rating for HAE, as published in its report on September 10, 2024. Needham’s report from June 12, 2024 suggests a price prediction of $112 for HAE shares, giving the stock a ‘Buy’ rating. Mizuho also rated the stock as ‘Buy’.
Analysis of Haemonetics Corp (HAE)
Further, the quarter-over-quarter increase in sales is 8.59%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Haemonetics Corp’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of 13.97% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.09, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and HAE is recording an average volume of 586.49K. On a monthly basis, the volatility of the stock is set at 3.73%, whereas on a weekly basis, it is put at 4.37%, with a loss of -2.92% over the past seven days. Furthermore, long-term investors anticipate a median target price of $110.80, showing growth from the present price of $72.86, which can serve as yet another indication of whether HAE is worth investing in or should be passed over.
How Do You Analyze Haemonetics Corp Shares?
A leading company in the Medical Instruments & Supplies sector, Haemonetics Corp (HAE) is based in the USA. When comparing Haemonetics Corp shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 30.26, there is a growth in quarterly earnings of 36.24%.
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.11%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 112.07% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
HAE shares are owned by institutional investors to the tune of 112.07% at present.
